Bluebird Bio Stock Today
| BLUE Stock | USD 4.02 0.03 0.74% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Bluebird Bio is trading at 4.02 as of the 26th of February 2025, a 0.74 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.85. Bluebird Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. The company has 9.72 M outstanding shares of which 2.53 M shares are currently shorted by private and institutional investors with about 12.75 trading days to cover. More on Bluebird bio
Moving against Bluebird Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bluebird Stock Highlights
| CEO President | Andrew Obenshain |
| Old Name | Blue Solutions SA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Jakarta Stock Exchange, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Bluebird bio (BLUE) is traded on NASDAQ Exchange in USA. It is located in 455 Grand Union Boulevard, Somerville, MA, United States, 02145 and employs 282 people. Bluebird Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.37 M. Bluebird bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.72 M outstanding shares of which 2.53 M shares are currently shorted by private and institutional investors with about 12.75 trading days to cover.
Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Check Bluebird Bio Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Bluebird bio is $39.37 Million. 30% of Bluebird bio outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Bluebird Ownership Details
Bluebird bio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bluebird Bio market risk premium is the additional return an investor will receive from holding Bluebird Bio long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0147 | |||
| Jensen Alpha | 0.1085 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0084 |
Bluebird Stock Against Markets
Bluebird Bio Corporate Management
| Mr MD | Chief Officer | Profile | |
| Melissa Bonner | VP Research | Profile | |
| Andrea Walton | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Christopher CPA | Principal CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.